The ADVN aims to understand immune responses in AD patients after natural exposure to skin viruses and investigate their reactions to the smallpox vaccine. The network will inform safer vaccine design, improving protection against the smallpox virus without life-threatening complications.
The NIAID-licensed rotavirus vaccine has been developed to combat severe diarrhea in infants and young children worldwide. The vaccine has shown promise in reducing the number of deaths caused by rotavirus infections, particularly in developing countries where access to effective treatments is limited.
Researchers develop two SARS vaccine candidates that effectively protect mice from infection, utilizing different technologies to stimulate the immune system. The vaccines target the S protein, a key component of the coronavirus responsible for initiating infection.
The NIAID-developed DNA vaccine significantly reduced SARS virus levels in infected mice, with antibodies alone responsible for the dramatic reduction. This breakthrough demonstrates the effectiveness of a novel vaccine approach against SARS, paving the way for future human clinical trials.
Cryptosporidium is missing two critical organelles commonly found in related protozoan parasites, including the apicoplast and mitochondrion. This discovery provides valuable opportunities to study the organism's biology and develop targeted treatments.
Researchers have successfully tested a new plague vaccine in a real-world mouse model, showing promising results. The vaccine was tested in a natural transmission setting, where infected fleas fed on vaccinated mice, and showed protection against the disease.
Researchers at NIAID have found that mouse immune systems produce antibodies capable of single-handedly neutralizing the SARS virus. This discovery confirms that vaccines triggering antibodies to the SARS virus are on the right track, and could lead to a faster development of effective vaccines or antiviral drugs.
Researchers found that a new MVA vaccine was effective in protecting monkeys from both smallpox and monkeypox. The vaccine elicited similar immune responses as the current Dryvax vaccine, with all immunized animals surviving a lethal monkeypox infection and showing no clinical signs of disease.
Research finds HIV-positive men who have persistent GBV-C infection survive longer, but the exact reason is unknown. The study of 271 participants found that those with long-term GBV-C infection lived up to 11 years after contracting HIV.
Researchers at Dana-Farber Cancer Institute have identified a protein, TRIM5-alpha, that blocks HIV replication in monkey cells. This discovery opens new avenues for intervening in early HIV infection and provides critical insights into viral uncoating, a little understood step in the viral lifecycle.
The database provides survival rates of people who received cell grafts, helping doctors evaluate the potential risks and benefits of transplantation in treating disorders like leukemia. Researchers can generate hypotheses on the role of donor matching in blood and marrow stem cell transplants with this new resource.
A recent study found that children who experienced fewer fevers in their first year were less likely to develop allergies by age 6. Researchers discovered that fever-inducing infections involving the eyes, ears, nose, or throat appeared to be associated with a lower risk of developing allergies.
Researchers have found that bacterial DNA from probiotics can reduce inflammation in mice with experimental colitis. The study discovered that purified probiotic DNA activates a specific element within the innate immune system, which helps to slow down inflammation.
A new recombinant tuberculosis vaccine is being tested in a Phase I clinical trial in the United States, combining two proteins known to stimulate strong immune responses in humans. The vaccine aims to offer protection against pulmonary TB, the most contagious form of the disease.
Researchers found a link between a family of antioxidant-related genes and the allergic response to diesel exhaust particles. The study suggests that people lacking these genes may have difficulty fighting air pollution's harmful effects, with potential treatments being explored.
Researchers found that starting with a combination of zidovudine, lamivudine, and efavirenz resulted in delayed failure of subsequent regimens and lower risk of drug resistance. The study suggests using sequential three-drug regimens may be more effective than four-drug treatments for treating first-time HIV recipients.
The first human trial of a DNA Ebola vaccine opened at the NIH Clinical Center in Bethesda. Twenty-seven volunteers will receive either the investigational vaccine or a placebo injection over two months and be followed for one year.
The NIAID initiative addresses primary immune deficiency diseases by focusing research priorities and uniting established researchers with new investigators. A cell line repository and Web-based patient registry will also be created to advance understanding of these lesser-known diseases.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded grants to fund the construction of six biosafety laboratories, including three NBLs and three RBLs. The new labs will provide a safe environment for scientists to conduct critical research on infectious diseases and bioterrorism.
Four research organizations will receive funding to develop promising HIV vaccine candidates using DNA vaccines, virus vector vaccines, subunit vaccines, and virus-like particle vaccines. Researchers aim to induce strong cellular and antibody immune responses in animal models.
The NIAID Biodefense Research Agenda has made significant strides in developing vaccines, treatments, and diagnostics for bioterror agents. The Institute has expanded partnerships with industry and academia to accelerate research and development of countermeasures.
The NIH has awarded $51 million to fund the Autoimmunity Centers of Excellence program, which aims to develop new immune-based therapies for autoimmune diseases. This expansion will enhance interactions between scientists and clinicians to accelerate translation of research findings into medical applications.
The NIH has awarded $85 million to five cooperative centers for translational research on human immunology and biodefense. Researchers will develop new ways to analyze immune cells and use imaging technologies to study vaccine responses, aiming to strengthen the immune system against diseases.
A long-term study found that nevirapine sustained a 41% reduction in HIV infection risk compared to azidothymidine (AZT) in infants born to breastfeeding mothers. The regimen showed significant cost savings, approximately 70 times less than AZT treatment.
A malaria vaccine trial has begun in Mali with support from NIAID, aiming to prevent the deadliest form of malaria. The FMP-1 vaccine, developed by WRAIR and GSK Biologicals, will be tested on 40 adults for one year to assess its safety and efficacy.
The NIAID has launched a clinical trial to test an immunoglobulin product containing antibodies to West Nile virus (WNV) in treating severe WNV encephalitis. The study aims to assess the safety and efficacy of this treatment in preventing death or neurologic disability.
The National Institute of Allergy and Infectious Diseases is launching a new program to support interdisciplinary research on infectious diseases, with eight regional centers expected to be established. The program aims to develop new therapies, vaccines, diagnostics, and tools to combat bioterrorism and emerging diseases.
Researchers found no evidence of persistent cytokine increase or link between cytokines and anthrax toxin effects, contradicting earlier beliefs. The study suggests that current efforts to design cytokine-suppressing drugs may be misguided.
Researchers at the NIH/NIAID have discovered that streptococcal infections trigger altered gene expression in neutrophil white blood cells, exposing potential targets for new treatments. The findings provide insight into how these common bacteria evade immune defenses.
Researchers found that structured treatment interruption in people with multidrug-resistant HIV led to more HIV-related complications and poorer immune response. The study suggests that continuing therapy guided by HIV drug resistance testing is a better approach for this group of HIV-infected individuals.
A mystery illness in western Montana was solved by researchers identifying the cause as Borrelia hermsii, a spiral-shaped bacterium. The disease is curable with antibiotics and can cause recurrent febrile illnesses, highlighting the potential for emerging diseases in previously unrecognised areas.
A live but weakened virus is being tested as a potential West Nile virus vaccine, with promising results showing high levels of protective antibodies in monkeys. The vaccine has been shown to be effective in preventing the disease-causing virus while triggering a strong immune response.
Scientists at NIAID and USAMRIID developed a prime-boost vaccine strategy that protects monkeys from Ebola infection. The boost alone shows promise in offering quick but weaker immune response.
Researchers discovered Trif, a critical transducer protein in the innate immune system, which mediates signals from both bacterial and viral infections. The protein's role sparks inflammation, making it an attractive target for drugs designed to combat runaway inflammation characteristic of infectious diseases.
The updated Guidelines provide practitioners with a list of suggested combination regimens for the initiation of antiretroviral therapy, taking into consideration factors such as potency, toxicities, and dosing frequency. The revised document aims to simplify the process of selecting an effective treatment regimen for HIV/AIDS patients.
The NIAID is distributing the GeneChip SARS Array at no cost to qualified researchers worldwide, providing a powerful tool to better understand the SARS coronavirus and its spread. The array will help scientists achieve objectives such as constructing a family tree of SARS coronaviruses and tracing the virus's evolution.
A new study has identified a special type of idiopathic hypereosinophilic syndrome (HES) that can be diagnosed with a tryptase blood test and treated successfully with imatinib. The disease, characterized by an overabundance of white blood cells called eosinophils, can cause severe organ damage and is often fatal.
Researchers identified nearly 300 asthma signature genes involved in pathogenesis, including arginase, which triggers asthmatic symptoms. The discovery could lead to targeted treatments for individual patients.
A new clinical trial shows that antifungal prophylaxis with itraconazole reduces fungal infection risk in children with chronic granulomatous disease (CGD). The study found a statistically significant reduction in cases, suggesting the addition of itraconazole to treatment regimens.
A national survey found significant support for HIV vaccine research, with 84% of the public believing efforts to develop a vaccine are 'extremely' or 'very' important. However, there is also concern about misconceptions about vaccine development and testing. The survey highlighted the need for education on ongoing HIV vaccine research.
Researchers from The Institute of Genomic Research sequenced B. anthracis genome to improve vaccine design and drug development. Despite similarities with closely related bacteria, the study found unique genes giving B. anthracis its ability to thrive on protein-rich matter.
Researchers identify viral protease NS3/4A as a key player in evading the immune system, leading to new avenues for clinical and basic research on hepatitis C. Inhibiting this protease restores the host's immune response, reducing viral levels to nearly undetectable levels.
Researchers discovered TB bacteria use an error-prone DNA polymerase, DnaE2, to introduce mutations and increase drug resistance. The enzyme plays a key role in the emergence of multidrug-resistant tuberculosis.
Scientists have discovered how the strep bacterium evades destruction by the human immune system, leading to new research on vaccine candidates and therapy interventions. The study found that GAS becomes more resilient to ingestion and killing by PMNs over time or produces factors that alter normal PMN function.
The HHS research plan aims to improve understanding of autoimmune diseases through genetic and environmental factor studies. The plan also calls for developing new treatments and diagnostics, as well as public education campaigns.
Scientists are developing an encyclopedia of innate immune system activity using systems biology approaches. This could lead to a better understanding of inflammation and its control, potentially revealing targets for new drugs. The study also explores the use of bioinformatics resources to support research on immune-mediated diseases.
Researchers discovered that an individual could become infected with two closely related strains of HIV, highlighting the challenges in creating a vaccine against this highly variable virus. The study found that a hypothetical vaccine against one strain may not protect against other closely related strains.
A major herpes vaccine trial is underway for women to prevent genital herpes, with over 70% of HSV-1 and HSV-2 negative women showing protection against the disease. The trial aims to recruit thousands of HSV-negative women to test the efficacy of a subunit vaccine containing a piece of the virus outer coat.
A new DNA vaccine has entered human trials, incorporating parts of four HIV genes to target various subtypes. The trial aims to determine the vaccine's safety and immune response, with expanded tests planned for international sites.
The Jordan Report 20th Anniversary outlines significant advancements in vaccine research for diseases like HIV/AIDS, tuberculosis, malaria, and bioterrorism threats. The report emphasizes the importance of vaccines in preventing illness and death from infectious diseases.